sumatriptan has been researched along with Nausea in 58 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Longitudinal nausea trajectories differed for AVP-825 and oral sumatriptan in the Overall Nausea model (Model 1) and TEN model (Model 2), but were more comparable across treatments for the Nausea Relief (Model 3)." | 9.27 | AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Silberstein, SD; Wirth, RJ, 2018) |
| "To test the hypothesis that sumatriptan iontophoretic transdermal system (TDS) is associated with lower rates of treatment-emergent nausea (TEN) relative to placebo, as well as to compare the efficacy of sumatriptan TDS in migraineurs with or without nausea at baseline." | 9.20 | Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. ( Bigal, ME; Lipton, RB; Newman, LC; Pierce, MW; Silberstein, SD, 2015) |
| "To evaluate the efficacy and safety of transdermal sumatriptan in migraine patients who have baseline nausea." | 9.16 | Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. ( Schulman, EA, 2012) |
| "To examine the effectiveness of a 5-HT(1B/1D) receptor agonist, sumatriptan, on a paroxysmal pain in trigeminal neuralgia." | 9.12 | Subcutaneous sumatriptan for refractory trigeminal neuralgia. ( Hoka, S; Kanai, A; Saito, M, 2006) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 7.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "To describe a patient with cyclic vomiting who was treated successfully with sumatriptan, a serotonin, agonist." | 7.69 | Sumatriptan in the treatment of cyclic vomiting. ( Benson, JM; Book, LS; Zorn, SL, 1995) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "Longitudinal nausea trajectories differed for AVP-825 and oral sumatriptan in the Overall Nausea model (Model 1) and TEN model (Model 2), but were more comparable across treatments for the Nausea Relief (Model 3)." | 5.27 | AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Silberstein, SD; Wirth, RJ, 2018) |
| "To test the hypothesis that sumatriptan iontophoretic transdermal system (TDS) is associated with lower rates of treatment-emergent nausea (TEN) relative to placebo, as well as to compare the efficacy of sumatriptan TDS in migraineurs with or without nausea at baseline." | 5.20 | Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. ( Bigal, ME; Lipton, RB; Newman, LC; Pierce, MW; Silberstein, SD, 2015) |
| "To evaluate the efficacy and safety of transdermal sumatriptan in migraine patients who have baseline nausea." | 5.16 | Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. ( Schulman, EA, 2012) |
| " From November 2001 to March 2002, patients meeting International Headache Society criteria for migraine (with > or =2 of the following: unilateral location, pulsating quality, moderate or severe intensity, aggravation by moderate physical activity; and > or =1 of: phonophobia and phonophobia, nausea and/or vomiting) and with no evidence of bacterial rhinosinusitis were enrolled and randomized in a 1:1 ratio via computer-generated randomization schedule to receive either 1 sumatriptan 50-mg tablet or matching placebo tablet." | 5.12 | Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. ( Ames, M; Blumenthal, H; Ishkanian, G; Richardson, MS; Webster, CJ, 2007) |
| "To examine the effectiveness of a 5-HT(1B/1D) receptor agonist, sumatriptan, on a paroxysmal pain in trigeminal neuralgia." | 5.12 | Subcutaneous sumatriptan for refractory trigeminal neuralgia. ( Hoka, S; Kanai, A; Saito, M, 2006) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.89 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; Moore, RA, 2013) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.86 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010) |
| "This pooled analysis (N=1773) used data from three randomized, placebo-controlled, phase III trials (studies A, B, and C) to determine the incidence of migraine-associated symptoms (defined as nausea, vomiting, photophobia, and phonophobia) 2 hours after a single oral dose of study medication (almotriptan, sumatriptan, or placebo)." | 4.81 | Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. ( Cady, R, 2002) |
| "Sumatriptan is a 5-HT1B/D receptor agonist of documented efficacy in relieving migraine and associated symptoms such as nausea and vomiting." | 4.81 | Gastric motor effects of triptans: open questions and future perspectives. ( Cipolla, G; Crema, F; De Ponti, F; Frigo, G; Moro, E; Sacco, S, 2001) |
| "Sumatriptan succinate and prochlorperazine maleate are a clinically proven combination for treating migraine and associated nausea and vomiting." | 4.12 | Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization. ( Anwer, UU; Bukhari, NI; Hafiz, MA; Hussain, A; Javed, S; Rasool, F; Raza, SA; Shah, PA; Shamim, R, 2022) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 3.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "To describe a patient with cyclic vomiting who was treated successfully with sumatriptan, a serotonin, agonist." | 3.69 | Sumatriptan in the treatment of cyclic vomiting. ( Benson, JM; Book, LS; Zorn, SL, 1995) |
| "4% (16/119) who received placebo experienced at least 1 treatment-emergent adverse event (TEAE), the most common of which were injection site swelling (7." | 2.87 | Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| "6% (89/219) of subjects reported treatment-emergent adverse events (TEAE), the most common of which were associated with the injection site: swelling (12." | 2.87 | Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| "Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting." | 2.80 | Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack. ( Ghaderibarmi, F; Tavakkoli, N; Togha, M, 2015) |
| " Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy." | 2.77 | Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| "Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome." | 2.73 | Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. ( Ames, MH; Byrd, SC; Couch, JR; Goldstein, J; Lener, SE; Mannix, LK; McDonald, SA; Silberstein, SD; Toso, C, 2008) |
| "In some cases photo- and/or phonophobia (hyperexcitability) were not experienced at all, despite severe pain and nausea." | 2.72 | The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. ( Dahlöf, C; Linde, M; Mellberg, A, 2006) |
| "Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published." | 2.71 | Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. ( Baggish, J; Battikha, JP; Elkind, AH; Gallagher, RM; Goldstein, J; Hoffman, H; Saper, JR; Silberstein, SD; Smith, TR, 2005) |
| "The sumatriptan dose was 10 mg for a body weight of 20 to 39 kg and 20 mg for those with a body weight of >/==" BORDER="0">40 kg." | 2.71 | Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. ( Ahonen, K; Hämäläinen, ML; Hoppu, K; Rantala, H, 2004) |
| "Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg." | 2.70 | Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. ( Géraud, G; Keywood, C; Spierings, EL, 2002) |
| "Sumatriptan nasal spray was well tolerated, the incidence of adverse events with each dose of sumatriptan being similar to the placebo (20-27 and 23%, respectively)." | 2.69 | Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. ( Ashford, EA; Becker, WJ; Dahlof, C; Hassani, H; Peikert, A; Salonen, RJ, 1999) |
| "Three-hundred-and-twenty-eight migraine sufferers treated a first migraine attack with a nontriptan standard care medication: a mixture containing phenazone, butalbital and caffeine (optalidon) or indomethacin plus prochlorperazine plus caffeine (difmetre) or paracetamol 100 mg (tachipirine), depending on their habits." | 2.69 | Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group. ( Cavazzuti, L; Fabbri, L; Pini, LA, 1999) |
| "Oral sumatriptan 100 mg was well tolerated, and repeated administration did not alter the pattern or severity of adverse events." | 2.68 | Oral sumatriptan for the long-term treatment of migraine: clinical findings. ( Cutler, N; Hazelrigg, R; Jamerson, B; Rapoport, A; Rederich, G, 1995) |
| "5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%)." | 2.68 | Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. ( Sawyer, J; Schoenen, J, 1997) |
| "More sumatriptan-treated patients were completely pain free compared with placebo-treated patients at both 2 h (24% versus 12%) and 4 h (48% versus 18)." | 2.67 | Oral sumatriptan compared with placebo in the acute treatment of migraine. ( Byrne, M; Nappi, G; Roncolato, M; Sicuteri, F; Zerbini, O, 1994) |
| "Other migraine symptoms (nausea, vomiting, photo- and phonophobia) were effectively treated with sumatriptan." | 2.67 | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. ( Bulcke, J; Caekebeke, J; De Keyser, J; Dehaene, I; Hildebrand, G; Joffroy, A; Laloux, P; Louis, P; Monseu, G; Schoenen, J, 1994) |
| "Sumatriptan was well tolerated and the majority of adverse events were mild and transient." | 2.67 | Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being. ( Dahlöf, C; Edwards, C; Toth, A, 1992) |
| "Patients treated up to three migraine attacks at home over a 3-month period and recorded the results on a diary card." | 2.67 | Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. ( , 1991) |
| "Sumatriptan was significantly more effective than placebo in relieving headache (moderate/severe reduced to mild/none) at 2 h (50 vs." | 2.67 | Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. ( , 1991) |
| "Sumatriptan was significantly more effective than Cafergot at reducing the intensity of headache from severe or moderate to mild or none; 66% (145/220) of those treated with sumatriptan improved in this way by 2 h, compared with 48% (118/246) of those treated with Cafergot (p less than 0." | 2.67 | A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. ( , 1991) |
| "If the migraine had not improved at 1 h, patients had the option of taking a second identical injection." | 2.67 | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. ( , 1991) |
| "A similar number of patients reported migraine recurrence, within 24 h in both treatment groups." | 2.67 | A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. ( , 1991) |
| "Diclofenac is an established analgesic, and new formulations using the potassium or epolamine salts, which can be dissolved in water, have been developed for rapid absorption, which may be beneficial in acute migraine." | 2.49 | Diclofenac with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA; Rabbie, R, 2013) |
| "Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients." | 2.49 | Sumatriptan iontophoretic transdermal system: history, study results, and use in clinical practice. ( Felker, E; O'Neill, C; Pierce, M; Sebree, T, 2013) |
| "Naproxen is a non-steroidal anti-inflammatory drug (NSAID); its efficacy in acute migraine has not been established by systematic reviews." | 2.49 | Naproxen with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Law, S; Moore, RA, 2013) |
| "The features of migraine attacks and the contexts in which migraine attacks occur vary from attack to attack and from patient to patient." | 2.48 | Therapeutic applications for subcutaneous triptans in the acute treatment of migraine. ( Erlichson, K; Waight, J, 2012) |
| "Diclofenac is an established analgesic, and new formulations using the potassium or epolamine salts, which can be dissolved in water, have been developed for rapid absorption, which may be beneficial in acute migraine." | 2.48 | Diclofenac with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA; Rabbie, R, 2012) |
| "Many migraineurs awake early in the morning with their attack progressing and already associated with nausea and vomiting." | 2.46 | Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. ( Freitag, F; Pearlman, SH; Rapoport, AM, 2010) |
| " Safety was evaluated based on the frequency of reported adverse events, and treatment with eASA was associated with lower incidence of adverse events than was with sumatriptan." | 2.44 | Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. ( Diener, HC; Lampl, C; Voelker, M, 2007) |
| "Sumatriptan was then launched as an oral tablet, shortly followed by the development of second-generation triptans that are now available in several formulations." | 2.42 | Clinical applications of new therapeutic deliveries in migraine. ( Dahlöf, C, 2003) |
| "Most patients with migraine consider drugs that can be administered orally to be the most user-friendly." | 2.41 | Integrating the triptans into clinical practice. ( Dahlöf, C, 2002) |
| " Zolmitriptan introduced in 1994 is an agonists of 5-HT 1B/1D receptor, is active both peripherally and centrally, is well absorbed from the digestive tract and has a good bioavailability index /40%/." | 2.40 | [Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor]. ( Prusiński, A, 1999) |
| "Sumatriptan is a potent and selective agonist at a vascular serotonin1 (5-hydroxytryptamine1; 5-HT1) receptor subtype (similar to 5-HT1D) and is used in acute treatment of migraine and cluster headache." | 2.39 | Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. ( McTavish, D; Plosker, GL, 1994) |
| "However, patients who experience migraine-associated nausea and/or vomiting can have difficulty swallowing tablets and may delay taking anti-migraine medication." | 1.43 | Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine. ( Chaudhry, H; Cohen, SP, 2016) |
| "Ten patients with acute, non-medicated, migraine (15 attacks) were assessed for severity of headache and associated symptoms (nausea, vomiting and photophobia)." | 1.28 | Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine. ( Advenier, C; Bayliss, EM; Bons, J; Brion, N; Plas, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.17) | 18.7374 |
| 1990's | 18 (31.03) | 18.2507 |
| 2000's | 17 (29.31) | 29.6817 |
| 2010's | 17 (29.31) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Javed, S | 1 |
| Hussain, A | 1 |
| Shah, PA | 1 |
| Raza, SA | 1 |
| Anwer, UU | 1 |
| Shamim, R | 1 |
| Rasool, F | 1 |
| Hafiz, MA | 1 |
| Bukhari, NI | 1 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Falkenberg, K | 1 |
| Bjerg, HR | 1 |
| Olesen, J | 1 |
| Lipton, RB | 3 |
| McGinley, JS | 1 |
| Shulman, KJ | 1 |
| Silberstein, SD | 4 |
| Wirth, RJ | 1 |
| Buse, DC | 1 |
| Landy, S | 3 |
| Munjal, S | 2 |
| Brand-Schieber, E | 2 |
| Rapoport, AM | 3 |
| Kirthi, V | 2 |
| Derry, S | 5 |
| Moore, RA | 5 |
| Rabbie, R | 2 |
| Pierce, M | 1 |
| O'Neill, C | 1 |
| Felker, E | 1 |
| Sebree, T | 1 |
| Law, S | 1 |
| Bigal, ME | 1 |
| Newman, LC | 1 |
| Pierce, MW | 2 |
| Ghaderibarmi, F | 1 |
| Tavakkoli, N | 1 |
| Togha, M | 1 |
| Cohen, SP | 1 |
| Chaudhry, H | 1 |
| Mannix, LK | 1 |
| Goldstein, J | 3 |
| Couch, JR | 1 |
| Byrd, SC | 1 |
| Ames, MH | 1 |
| McDonald, SA | 1 |
| Lener, SE | 1 |
| Toso, C | 1 |
| Kostic, MA | 1 |
| Gutierrez, FJ | 1 |
| Rieg, TS | 1 |
| Moore, TS | 1 |
| Gendron, RT | 1 |
| McQuay, HJ | 1 |
| Freitag, F | 1 |
| Pearlman, SH | 1 |
| Schulman, EA | 1 |
| Smith, TR | 2 |
| Singer, R | 1 |
| Pugach, N | 1 |
| Silberstein, S | 1 |
| Erlichson, K | 1 |
| Waight, J | 1 |
| Dahlöf, C | 5 |
| Ahonen, K | 1 |
| Hämäläinen, ML | 1 |
| Rantala, H | 1 |
| Hoppu, K | 1 |
| Igarashi, H | 1 |
| Savani, N | 1 |
| Shackelford, S | 1 |
| Loftus, J | 1 |
| Jones, M | 1 |
| Saper, JR | 1 |
| Elkind, AH | 1 |
| Gallagher, RM | 1 |
| Battikha, JP | 1 |
| Hoffman, H | 1 |
| Baggish, J | 1 |
| Winner, P | 1 |
| Rothner, AD | 1 |
| Wooten, JD | 1 |
| Webster, C | 1 |
| Ames, M | 2 |
| Kanai, A | 1 |
| Saito, M | 1 |
| Hoka, S | 1 |
| Linde, M | 1 |
| Mellberg, A | 1 |
| Ishkanian, G | 1 |
| Blumenthal, H | 1 |
| Webster, CJ | 1 |
| Richardson, MS | 1 |
| Lampl, C | 1 |
| Voelker, M | 1 |
| Diener, HC | 1 |
| Plosker, GL | 1 |
| McTavish, D | 1 |
| Rederich, G | 1 |
| Rapoport, A | 1 |
| Cutler, N | 1 |
| Hazelrigg, R | 1 |
| Jamerson, B | 1 |
| Färkkilä, M | 1 |
| Nappi, G | 1 |
| Sicuteri, F | 1 |
| Byrne, M | 1 |
| Roncolato, M | 1 |
| Zerbini, O | 1 |
| Schoenen, J | 2 |
| Bulcke, J | 1 |
| Caekebeke, J | 1 |
| Dehaene, I | 1 |
| De Keyser, J | 1 |
| Hildebrand, G | 1 |
| Joffroy, A | 1 |
| Laloux, P | 1 |
| Louis, P | 1 |
| Monseu, G | 1 |
| Benson, JM | 1 |
| Zorn, SL | 1 |
| Book, LS | 1 |
| Boeles, S | 1 |
| Williams, C | 1 |
| Campling, GM | 1 |
| Goodall, EM | 1 |
| Cowen, PJ | 1 |
| Sawyer, J | 1 |
| Peikert, A | 1 |
| Becker, WJ | 1 |
| Ashford, EA | 1 |
| Hassani, H | 1 |
| Salonen, RJ | 1 |
| Pini, LA | 1 |
| Fabbri, L | 1 |
| Cavazzuti, L | 1 |
| Géraud, G | 2 |
| Valette, C | 1 |
| Prusiński, A | 1 |
| Cipolla, G | 1 |
| Sacco, S | 1 |
| Crema, F | 1 |
| Moro, E | 1 |
| De Ponti, F | 1 |
| Frigo, G | 1 |
| Pascual, J | 1 |
| Goadsby, PJ | 1 |
| Massiou, H | 1 |
| McCarroll, KA | 1 |
| Vandormael, K | 1 |
| Jiang, K | 1 |
| Lines, CR | 1 |
| Cady, R | 1 |
| Spierings, EL | 1 |
| Keywood, C | 1 |
| Edwards, C | 1 |
| Toth, A | 1 |
| Houghton, LA | 1 |
| Fowler, P | 1 |
| Keene, ON | 1 |
| Read, NW | 1 |
| Brion, N | 1 |
| Bons, J | 1 |
| Plas, J | 1 |
| Bayliss, EM | 2 |
| Advenier, C | 1 |
| Baar, HA | 1 |
| Brand, J | 1 |
| Doenicke, A | 2 |
| Melchart, D | 2 |
| Lüben, V | 1 |
| Tryba, M | 1 |
| Sahlender, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02569853] | Phase 3 | 268 participants (Actual) | Interventional | 2015-09-21 | Completed | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130] | Phase 4 | 58 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103] | Phase 3 | 198 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02569853)
Timeframe: 1 hour
| Intervention | Percentage of responders (Number) |
|---|---|
| DFN-11 | 34.6 |
| Placebo | 19.8 |
(NCT02569853)
Timeframe: 2 hours
| Intervention | Percentage of responders (Number) |
|---|---|
| DFN-11 - Double-Blind | 51.0 |
| Placebo - Double-Blind | 30.8 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 143 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 105 |
Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 109 |
Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participant (Number) |
|---|---|
| NP101 | 97 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation
| Intervention | scores on a scale (Mean) |
|---|---|
| NP101 | 1.0 |
18 reviews available for sumatriptan and Nausea
| Article | Year |
|---|---|
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2013 |
Diclofenac with or without an antiemetic for acute migraine headaches in adults.
Topics: Acute Disease; Adult; Analgesics; Antiemetics; Diclofenac; Drug Therapy, Combination; Female; Humans | 2013 |
Sumatriptan iontophoretic transdermal system: history, study results, and use in clinical practice.
Topics: Administration, Cutaneous; Animals; Clinical Trials as Topic; Drug Delivery Systems; Humans; Iontoph | 2013 |
Naproxen with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Drug Therapy, Combination; Humans; Migr | 2013 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2010 |
Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
Topics: Clinical Trials as Topic; Drug Administration Routes; Female; Gastroparesis; Humans; Iontophoresis; | 2010 |
Diclofenac with or without an antiemetic for acute migraine headaches in adults.
Topics: Acute Disease; Adult; Analgesics; Antiemetics; Diclofenac; Drug Therapy, Combination; Humans; Hypera | 2012 |
Therapeutic applications for subcutaneous triptans in the acute treatment of migraine.
Topics: Humans; Injections, Subcutaneous; Migraine Disorders; Nausea; Sumatriptan; Treatment Outcome | 2012 |
Clinical applications of new therapeutic deliveries in migraine.
Topics: Administration, Intranasal; Administration, Oral; Adult; Clinical Trials as Topic; Dysgeusia; Female | 2003 |
[Side effects of triptans].
Topics: Central Nervous System; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Nause | 2004 |
Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relatio | 2007 |
Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Topics: Administration, Oral; Animals; Cluster Headache; Humans; Injections, Subcutaneous; Migraine Disorder | 1994 |
[New serotonin-receptor drugs for migraine and nausea].
Topics: Humans; Migraine Disorders; Nausea; Serotonin Antagonists; Sumatriptan | 1993 |
[Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Emergency Treatment; E | 1999 |
Gastric motor effects of triptans: open questions and future perspectives.
Topics: Forecasting; Gastrointestinal Motility; Humans; Indoles; Nausea; Piperidines; Serotonin Receptor Ago | 2001 |
Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Female; Humans; | 2002 |
Integrating the triptans into clinical practice.
Topics: Consumer Behavior; Drug Administration Routes; Drug Tolerance; Humans; Migraine Disorders; Nausea; S | 2002 |
32 trials available for sumatriptan and Nausea
| Article | Year |
|---|---|
AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.
Topics: Administration, Intranasal; Adult; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Hum | 2018 |
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Di | 2018 |
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Hyperacusis; Injections, Subcutaneous; Male; | 2018 |
Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Incidence; | 2015 |
Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Recurrence; Sumatriptan; Valpr | 2015 |
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migr | 2008 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
Topics: Adult; Akathisia, Drug-Induced; Analgesics; Conscious Sedation; Diphenhydramine; Double-Blind Method | 2010 |
Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind M | 2012 |
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu | 2012 |
Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.
Topics: Administration, Intranasal; Adolescent; Child; Cross-Over Studies; Dose-Response Relationship, Drug; | 2004 |
Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine.
Topics: Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Fatigue; Female; Humans; Menstrual Cycle; M | 2004 |
Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non- | 2005 |
Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Topics: Acute Disease; Administration, Inhalation; Administration, Intranasal; Adolescent; Dose-Response Rel | 2006 |
Subcutaneous sumatriptan for refractory trigeminal neuralgia.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Fatigue; Female; Humans; Injections, Subcutaneou | 2006 |
The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan.
Topics: Adult; Aged; Comorbidity; Cross-Over Studies; Disease Progression; Female; Humans; Hyperacusis; Inci | 2006 |
Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Female; Humans; Male; | 2007 |
Oral sumatriptan for the long-term treatment of migraine: clinical findings.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Lo | 1995 |
Oral sumatriptan compared with placebo in the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adult; Double-Blind Method; Female; Fever; Humans; Hypesthesia; | 1994 |
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study.
Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antieme | 1994 |
Sumatriptan decreases food intake and increases plasma growth hormone in healthy women.
Topics: Adult; Cross-Over Studies; Eating; Female; Human Growth Hormone; Humans; Nausea; Serotonin Receptor | 1997 |
Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Female; Humans; Menstruation; Midd | 1997 |
Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine.
Topics: Adult; Aerosols; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Humans; Hyper | 1999 |
Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group.
Topics: Adolescent; Adult; Aged; Analgesics; Double-Blind Method; Drug Resistance; Humans; Italy; Middle Age | 1999 |
[Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Dis | 2000 |
Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Topics: Acute Disease; Adult; Carbazoles; Clinical Trials as Topic; Dizziness; Dose-Response Relationship, D | 2002 |
Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being.
Topics: Acute Disease; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; | 1992 |
Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man.
Topics: Adult; Double-Blind Method; Fats; Gamma Cameras; Gastric Emptying; Half-Life; Humans; Indoles; Infus | 1992 |
Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group.
Topics: Administration, Oral; Adult; Consumer Behavior; Double-Blind Method; Female; Humans; Indoles; Male; | 1991 |
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up | 1991 |
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
Topics: Administration, Oral; Adult; Aged; Caffeine; Double-Blind Method; Drug Combinations; Electrocardiogr | 1991 |
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneo | 1991 |
A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group.
Topics: Absorption; Administration, Intranasal; Adult; Disability Evaluation; Double-Blind Method; Female; H | 1991 |
8 other studies available for sumatriptan and Nausea
| Article | Year |
|---|---|
Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization.
Topics: Excipients; Humans; Migraine Disorders; Nausea; Prochlorperazine; Sumatriptan; Vomiting | 2022 |
Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment.
Topics: Adult; Calcitonin Gene-Related Peptide; Constipation; Cross-Over Studies; Diarrhea; Double-Blind Met | 2020 |
Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine.
Topics: Europe; Female; Humans; Iontophoresis; Migraine Disorders; Nausea; Sumatriptan | 2016 |
Sumatriptan in the treatment of cyclic vomiting.
Topics: Abdominal Pain; Adult; Humans; Male; Nausea; Recurrence; Serotonin Receptor Agonists; Sumatriptan; V | 1995 |
Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Topics: Administration, Oral; Adult; Double-Blind Method; Humans; Indoles; Migraine Disorders; Nausea; Oxazo | 2001 |
Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Injections, Subcutaneous; Male; Mi | 1989 |
Treatment of acute migraine with subcutaneous GR43175 in West Germany.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Injections, Subcutaneous; Male; Mi | 1989 |
Effective improvement of symptoms in patients with acute migraine by GR43175 administered in dispersible tablets.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle | 1989 |